Labetuzumab govitecan

Drug Profile

Labetuzumab govitecan

Alternative Names: Anti-carcinoembryonic antigen monoclonal antibody; Anti-CEA monoclonal antibody; anti-CEACAM5-SN-38; hMN-14-SN38; hMN-14-SN38 antibody-drug conjugate; IMMU-130; Labetuzumab-SN38 conjugate; SN38-labetuzumab conjugate

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Monoclonal antibodies; Pyrans; Pyrrolidines; Quinolines; Triazoles
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer

Most Recent Events

  • 18 Jan 2017 Immunomedics completes enrolment in a phase II trial in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA
  • 22 Dec 2016 Immunomedics has patent protection for labetuzumab govitecan in USA
  • 20 Oct 2016 Immunomedics has patent protection for the use of labetuzumab govitecan combination and DNL® protein conjugation platform technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top